BMY — Bristol-Myers Squibb Company

Is BMY overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - General

Neutral As of November 17, 2026

Bristol-Myers Squibb Company (BMY) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - General) last closed at $61.35. The rating moved from Overbought to Neutral on November 16, 2026.

AI analysis

Bristol-Myers Squibb Company combines a diversified portfolio and steady cash generation with meaningful pipeline and specialty assets that provide medium-term growth optionality. Current market dynamics favor large-cap pharma as a defensive allocation, supporting relative stability while potential catalysts include clinical readouts, label expansions and opportunistic M&A. Key near-term risks include regulatory/payer pressure, patent and generic competition, and typical pipeline execution uncertainty; investors should weigh predictable cash flow and dividend support against these downside scenarios.

Key factors

  • Large-cap diversified pharmaceutical franchise with long-duration revenue streams and predictable cash flow profile
  • Defensive sector flows into large-cap pharma support relative outperformance in risk-off or consolidation market environments
  • Pipeline and specialty/immunology/oncology franchises provide medium-term revenue catalysts from readouts, label expansions, and potential partnering/M&A
  • History of shareholder returns via dividends and buybacks that support investor base stability
  • Industry consolidation tailwinds that may enable strategic M&A or asset monetization at attractive multiples
  • Limited near-term macro or geopolitical shocks in the market window, enabling focus on earnings and company-specific catalysts

Risks

  • Regulatory and pricing pressure, including potential downstream effects from Medicare Advantage integrity measures that could alter payer dynamics and negotiation leverage
  • Patent expirations, generic competition or volume erosion for key products that could pressure top-line growth
  • Clinical or regulatory setbacks in the pipeline that would reduce projected future revenue and valuation support
  • M&A/integration execution risk from acquisitions or divestitures that could strain margins or capital allocation
  • Litigation, settlement risk or unexpected one-time charges that could impact earnings
  • Broader market weakness or rotation away from defensive pharma into growth cyclicals that could reduce multiple expansion

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for BMY — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.